|
1
|
Santucci M, Vignudelli T, Ferrari S, Mor
M, Scalvini L, Bolognesi ML, Uliassi E and Costi MP: The Hippo
pathway and YAP/TAZ-TEAD protein-protein interaction as targets for
regenerative medicine and cancer treatment. J Med Chem.
58:4857–4873. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhao B, Li L, Lei Q and Guan KL: The
Hippo-YAP pathway in organ size control and tumorigenesis: An
updated version. Genes Dev. 24:862–874. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhao B, Tumaneng K and Guan KL: The Hippo
pathway in organ size control, tissue regeneration and stem cell
self-renewal. Nat Cell Biol. 13:877–883. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim
J, Xie J, Ikenoue T, Yu J, Li L, et al: Inactivation of YAP
oncoprotein by the Hippo pathway is involved in cell contact
inhibition and tissue growth control. Genes Dev. 21:2747–2761.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lei QY, Zhang H, Zhao B, Zha ZY, Bai F,
Pei XH, Zhao S, Xiong Y and Guan KL: TAZ promotes cell
proliferation and epithelial-mesenchymal transition and is
inhibited by the hippo pathway. Mol Cell Biol. 28:2426–2436. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cai J, Zhang N, Zheng Y, de Wilde RF,
Maitra A and Pan D: The Hippo signaling pathway restricts the
oncogenic potential of an intestinal regeneration program. Genes
Dev. 24:2383–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hong W and Guan KL: The YAP and TAZ
transcription co-activators: Key downstream effectors of the
mammalian Hippo pathway. Semin Cell Dev Biol. 23:785–793. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Barry ER, Morikawa T, Butler BL, Shrestha
K, de la Rosa R, Yan KS, Fuchs CS, Magness ST, Smits R, Ogino S, et
al: Restriction of intestinal stem cell expansion and the
regenerative response by YAP. Nature. 493:106–110. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ma Y, Yang Y, Wang F, Wei Q and Qin H:
Hippo-YAP signaling pathway: A new paradigm for cancer therapy. Int
J Cancer. 137:2275–2286. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mo JS, Park HW and Guan KL: The Hippo
signaling pathway in stem cell biology and cancer. EMBO Rep.
15:642–656. 2014.PubMed/NCBI
|
|
11
|
Pan D: The hippo signaling pathway in
development and cancer. Dev Cell. 19:491–505. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang L, Shi S, Guo Z, Zhang X, Han S, Yang
A, Wen W and Zhu Q: Overexpression of YAP and TAZ is an independent
predictor of prognosis in colorectal cancer and related to the
proliferation and metastasis of colon cancer cells. PLoS One.
8:e655392013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Halder G and Johnson RL: Hippo signaling:
Growth control and beyond. Development. 138:9–22. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Moroishi T, Hansen CG and Guan KL: The
emerging roles of YAP and TAZ in cancer. Nat Rev Cancer. 15:73–79.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Piccolo S, Dupont S and Cordenonsi M: The
biology of YAP/TAZ: Hippo signaling and beyond. Physiol Rev.
94:1287–1312. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Moroishi T, Park HW, Qin B, Chen Q, Meng
Z, Plouffe SW, Taniguchi K, Yu FX, Karin M, Pan D, et al: A
YAP/TAZ-induced feedback mechanism regulates Hippo pathway
homeostasis. Genes Dev. 29:1271–1284. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang L, Chen Z, Wang Y, Chang D, Su L, Guo
Y and Liu C: TR1 promotes cell proliferation and inhibits apoptosis
through cyclin A and CTGF regulation in non-small cell lung cancer.
Tumour Biol. 35:463–468. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nishioka N, Inoue K, Adachi K, Kiyonari H,
Ota M, Ralston A, Yabuta N, Hirahara S, Stephenson RO, Ogonuki N,
et al: The Hippo signaling pathway components Lats and Yap pattern
Tead4 activity to distinguish mouse trophectoderm from inner cell
mass. Dev Cell. 16:398–410. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xin M, Kim Y, Sutherland LB, Murakami M,
Qi X, McAnally J, Porrello ER, Mahmoud AI, Tan W, Shelton JM, et
al: Hippo pathway effector Yap promotes cardiac regeneration. Proc
Natl Acad Sci USA. 110:13839–13844. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zaidi SK, Sullivan AJ, Medina R, Ito Y,
van Wijnen AJ, Stein JL, Lian JB and Stein GS: Tyrosine
phosphorylation controls Runx2-mediated subnuclear targeting of YAP
to repress transcription. EMBO J. 23:790–799. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhou Z, Hu T, Xu Z, Lin Z, Zhang Z, Feng
T, Zhu L, Rong Y, Shen H, Luk JM, et al: Targeting Hippo pathway by
specific interruption of YAP-TEAD interaction using cyclic YAP-like
peptides. FASEB J. 29:724–732. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Varelas X: The Hippo pathway effectors TAZ
and YAP in development, homeostasis and disease. Development.
141:1614–1626. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Han SX, Bai E, Jin GH, He CC, Guo XJ, Wang
LJ, Li M, Ying X and Zhu Q: Expression and clinical significance of
YAP, TAZ, and AREG in hepatocellular carcinoma. J Immunol Res.
2014:2613652014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sudol M, Bork P, Einbond A, Kastury K,
Druck T, Negrini M, Huebner K and Lehman D: Characterization of the
mammalian YAP (Yes-associated protein) gene and its role in
defining a novel protein module, the WW domain. J Biol Chem.
270:14733–14741. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Morin-Kensicki EM, Boone BN, Howell M,
Stonebraker JR, Teed J, Alb JG, Magnuson TR, O'Neal W and Milgram
SL: Defects in yolk sac vasculogenesis, chorioallantoic fusion, and
embryonic axis elongation in mice with targeted disruption of
Yap65. Mol Cell Biol. 26:77–87. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Muramatsu T, Imoto I, Matsui T, Kozaki K,
Haruki S, Sudol M, Shimada Y, Tsuda H, Kawano T and Inazawa J: YAP
is a candidate oncogene for esophageal squamous cell carcinoma.
Carcinogenesis. 32:389–398. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gaffney CJ, Oka T, Mazack V, Hilman D, Gat
U, Muramatsu T, Inazawa J, Golden A, Carey DJ, Farooq A, et al:
Identification, basic characterization and evolutionary analysis of
differentially spliced mRNA isoforms of human YAP1 gene. Gene.
509:215–222. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yu FX, Luo J, Mo JS, Liu G, Kim YC, Meng
Z, Zhao L, Peyman G, Ouyang H, Jiang W, et al: Mutant Gq/11 promote
uveal melanoma tumorigenesis by activating YAP. Cancer Cell.
25:822–830. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hall CA, Wang R, Miao J, Oliva E, Shen X,
Wheeler T, Hilsenbeck SG, Orsulic S and Goode S: Hippo pathway
effector Yap is an ovarian cancer oncogene. Cancer Res.
70:8517–8525. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sudol M: Yes-associated protein (YAP65) is
a proline-rich phosphoprotein that binds to the SH3 domain of the
Yes proto-oncogene product. Oncogene. 9:2145–2152. 1994.PubMed/NCBI
|
|
31
|
Kanai F, Marignani PA, Sarbassova D, Yagi
R, Hall RA, Donowitz M, Hisaminato A, Fujiwara T, Ito Y, Cantley
LC, et al: TAZ: A novel transcriptional co-activator regulated by
interactions with 14-3-3 and PDZ domain proteins. EMBO J.
19:6778–6791. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li PD, Wang XJ, Shan Q, Wu YH and Wang Z:
Evaluation of TAZ expression and its effect on tumor invasion and
metastasis in human glioma. Asian Pac J Trop Med. 7:757–760. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nagaraj R, Gururaja-Rao S, Jones KT,
Slattery M, Negre N, Braas D, Christofk H, White KP, Mann R and
Banerjee U: Control of mitochondrial structure and function by the
Yorkie/YAP oncogenic pathway. Genes Dev. 26:2027–2037. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Guo L and Teng L: YAP/TAZ for cancer
therapy: Opportunities and challenges (Review). Int J Oncol.
46:1444–1452. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Oka T and Sudol M: Nuclear localization
and pro-apoptotic signaling of YAP2 require intact PDZ-binding
motif. Genes Cells. 14:607–615. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sawada A, Kiyonari H, Ukita K, Nishioka N,
Imuta Y and Sasaki H: Redundant roles of Tead1 and Tead2 in
notochord development and the regulation of cell proliferation and
survival. Mol Cell Biol. 28:3177–3189. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hiemer SE, Zhang L, Kartha VK, Packer TS,
Almershed M, Noonan V, Kukuruzinska M, Bais MV, Monti S and Varelas
X: A YAP/TAZ-Regulated Molecular Signature Is Associated with Oral
Squamous Cell Carcinoma. Mol Cancer Res. 13:957–968. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chan SW, Lim CJ, Chong YF, Pobbati AV,
Huang C and Hong W: Hippo pathway-independent restriction of TAZ
and YAP by angiomotin. J Biol Chem. 286:7018–7026. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Liu C, Huang W and Lei Q: Regulation and
function of the TAZ transcription co-activator. Int J Biochem Mol
Biol. 2:247–256. 2011.PubMed/NCBI
|
|
40
|
Yue G, Sun X, Gimenez-Capitan A, Shen J,
Yu L, Teixido C, Guan W, Rosell R, Liu B and Wei J: TAZ is highly
expressed in gastric signet ring cell carcinoma. BioMed Res Int.
2014:3930642014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Aqeilan RI, Donati V, Palamarchuk A,
Trapasso F, Kaou M, Pekarsky Y, Sudol M and Croce CM: WW
domain-containing proteins, WWOX and YAP, compete for interaction
with ErbB-4 and modulate its transcriptional function. Cancer Res.
65:6764–6772. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Donzelli S, Strano S and Blandino G: YAP
and p73: A matter of mutual specificity in tumor suppressionThe
Hippo Signaling Pathway and Cancer. Springer; New York: pp.
147–172. 2013, View Article : Google Scholar
|
|
43
|
Azzolin L, Zanconato F, Bresolin S,
Forcato M, Basso G, Bicciato S, Cordenonsi M and Piccolo S: Role of
TAZ as mediator of Wnt signaling. Cell. 151:1443–1456. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Low BC, Pan CQ, Shivashankar GV,
Bershadsky A, Sudol M and Sheetz M: YAP/TAZ as mechanosensors and
mechanotransducers in regulating organ size and tumor growth. FEBS
Lett. 588:2663–2670. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Acerbi I, Cassereau L, Dean I, Shi Q, Au
A, Park C, Chen YY, Liphardt J, Hwang ES and Weaver VM: Human
breast cancer invasion and aggression correlates with ECM
stiffening and immune cell infiltration. Integr Biol. 7:1120–1134.
2015. View Article : Google Scholar
|
|
46
|
Calvo F, Ege N, Grande-Garcia A, Hooper S,
Jenkins RP, Chaudhry SI, Harrington K, Williamson P, Moeendarbary
E, Charras G, et al: Mechanotransduction and YAP-dependent matrix
remodelling is required for the generation and maintenance of
cancer-associated fibroblasts. Nat Cell Biol. 15:637–646. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Halder G, Dupont S and Piccolo S:
Transduction of mechanical and cytoskeletal cues by YAP and TAZ.
Nat Rev Mol Cell Biol. 13:591–600. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Aragona M, Panciera T, Manfrin A, Giulitti
S, Michielin F, Elvassore N, Dupont S and Piccolo S: A mechanical
checkpoint controls multicellular growth through YAP/TAZ regulation
by actin-processing factors. Cell. 154:1047–1059. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Gibson WT and Gibson MC: Cell topology,
geometry, and morphogenesis in proliferating epithelia. Curr Top
Dev Biol. 89:87–114. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Vogel V and Sheetz M: Local force and
geometry sensing regulate cell functions. Nat Rev Mol Cell Biol.
7:265–275. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Furukawa KT, Yamashita K, Sakurai N and
Ohno S: The epithelial circumferential actin belt regulates YAP/TAZ
through nucleocytoplasmic shuttling of merlin. Cell Reports.
20:1435–1447. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Matsui Y and Lai ZC: Mutual regulation
between Hippo signaling and actin cytoskeleton. Protein Cell.
4:904–910. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Zhao B, Li L, Wang L, Wang CY, Yu J and
Guan KL: Cell detachment activates the Hippo pathway via
cytoskeleton reorganization to induce anoikis. Genes Dev. 26:54–68.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Wada K, Itoga K, Okano T, Yonemura S and
Sasaki H: Hippo pathway regulation by cell morphology and stress
fibers. Development. 138:3907–3914. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Sansores-Garcia L, Bossuyt W, Wada K,
Yonemura S, Tao C, Sasaki H and Halder G: Modulating F-actin
organization induces organ growth by affecting the Hippo pathway.
EMBO J. 30:2325–2335. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Talele NP, Fradette J, Davies JE, Kapus A
and Hinz B: Expression of α-smooth muscle actin determines the fate
of mesenchymal stromal cells. Stem Cell Reports. 4:1016–1030. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Miyabara S, Yuda Y, Kasashima Y, Kuwano A
and Arai K: Regulation of Tenomodulin Expression Via Wnt/β-catenin
Signaling in Equine Bone Marrow-derived Mesenchymal Stem Cells. J
Equine Sci. 25:7–13. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Lustig B and Behrens J: The Wnt signaling
pathway and its role in tumor development. J Cancer Res Clin Oncol.
129:199–221. 2003.PubMed/NCBI
|
|
59
|
Yu FX, Zhao B and Guan KL: Hippo pathway
in organ size control, tissue homeostasis, and cancer. Cell.
163:811–828. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Konsavage WM Jr and Yochum GS:
Intersection of Hippo/YAP and Wnt/β-catenin signaling pathways.
Acta Biochim Biophys Sin (Shanghai). 45:71–79. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Konsavage WM Jr, Kyler SL, Rennoll SA, Jin
G and Yochum GS: Wnt/β-catenin signaling regulates Yes-associated
protein (YAP) gene expression in colorectal carcinoma cells. J Biol
Chem. 287:11730–11739. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Huang W, Lv X, Liu C, Zha Z, Zhang H,
Jiang Y, Xiong Y, Lei QY and Guan KL: The N-terminal phosphodegron
targets TAZ/WWTR1 protein for SCFβ-TrCP-dependent degradation in
response to phosphatidylinositol 3-kinase inhibition. J Biol Chem.
287:26245–26253. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Nishita M, Endo M and Minami Y: Regulation
of cellular responses by non-canonical Wnt signaling. Clin Calcium.
23:809–815. 2013.(In Japanese). PubMed/NCBI
|
|
64
|
Korswagen HC: Canonical and non-canonical
Wnt signaling pathways in Caenorhabditis elegans: Variations on a
common signaling theme. BioEssays. 24:801–810. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Park HW, Kim YC, Yu B, Moroishi T, Mo JS,
Plouffe SW, Meng Z, Lin KC, Yu FX, Alexander CM, et al: Alternative
Wnt Signaling Activates YAP/TAZ. Cell. 162:780–794. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Azzolin L, Panciera T, Soligo S, Enzo E,
Bicciato S, Dupont S, Bresolin S, Frasson C, Basso G, Guzzardo V,
et al: YAP/TAZ incorporation in the β-catenin destruction complex
orchestrates the Wnt response. Cell. 158:157–170. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Varelas X, Miller BW, Sopko R, Song S,
Gregorieff A, Fellouse FA, Sakuma R, Pawson T, Hunziker W, McNeill
H, et al: The Hippo pathway regulates Wnt/beta-catenin signaling.
Dev Cell. 18:579–591. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Imajo M, Miyatake K, Iimura A, Miyamoto A
and Nishida E: A molecular mechanism that links Hippo signalling to
the inhibition of Wnt/β-catenin signalling. EMBO J. 31:1109–1122.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Lappano R and Maggiolini M: G
protein-coupled receptors: Novel targets for drug discovery in
cancer. Nat Rev Drug Discov. 10:47–60. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Prickett TD, Wei X, Cardenas-Navia I, Teer
JK, Lin JC, Walia V, Gartner J, Jiang J, Cherukuri PF, Molinolo A,
et al: Exon capture analysis of G protein-coupled receptors
identifies activating mutations in GRM3 in melanoma. Nat Genet.
43:1119–1126. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
71
|
Paschke R and Ludgate M: The thyrotropin
receptor in thyroid diseases. N Engl J Med. 337:1675–1681. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Hernández NA, Correa E, Avila EP, Vela TA
and Pérez VM: PAR1 is selectively over expressed in high grade
breast cancer patients: A cohort study. J Transl Med. 7:472009.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Guo X and Zhao B: Integration of
mechanical and chemical signals by YAP and TAZ transcription
coactivators. Cell Biosci. 3:332013. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Miller E, Yang J, DeRan M, Wu C, Su AI,
Bonamy GMC, Liu J, Peters EC and Wu X: Identification of
serum-derived sphingosine-1-phosphate as a small molecule regulator
of YAP. Chem Biol. 19:955–962. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Yu FX, Zhao B, Panupinthu N, Jewell JL,
Lian I, Wang LH, Zhao J, Yuan H, Tumaneng K, Li H, et al:
Regulation of the Hippo-YAP pathway by G-protein-coupled receptor
signaling. Cell. 150:780–791. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Waldron RT, Innamorati G, Torres-Marquez
ME, Sinnett-Smith J, Rozengurt E and RT W: Differential
PKC-dependent and -independent PKD activation by G protein α
subunits of the Gq family: Selective stimulation of PKD
Ser748 autophosphorylation by Gαq. Cell Signal.
24:914–921. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Wang J, Sinnett-Smith J, Stevens JV, Young
SH and Rozengurt E: Biphasic regulation of Yes-associated protein
(YAP) cellular localization, phosphorylation, and activity by G
protein-coupled receptor agonists in intestinal epithelial cells: A
novel role for protein kinase D (PKD). J Biol Chem.
291:17988–18005. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Hao F, Xu Q, Zhao Y, Stevens JV, Young SH,
Sinnett-Smith J and Rozengurt E: Insulin receptor and GPCR
crosstalk stimulates YAP via PI3K and PKD in pancreatic cancer
cells. Mol Cancer Res. 15:929–941. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Vigneron AM, Ludwig RL and Vousden KH:
Cytoplasmic ASPP1 inhibits apoptosis through the control of YAP.
Genes Dev. 24:2430–2439. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Hansen CG, Ng YL, Lam WL, Plouffe SW and
Guan KL: The Hippo pathway effectors YAP and TAZ promote cell
growth by modulating amino acid signaling to mTORC1. Cell Res.
25:1299–1313. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Kim M, Kim T, Johnson RL and Lim DS:
Transcriptional co-repressor function of the hippo pathway
transducers YAP and TAZ. Cell Reports. 11:270–282. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Zhou X, Wang S, Wang Z, Feng X, Liu P, Lv
XB, Li F, Yu FX, Sun Y, Yuan H, et al: Estrogen regulates Hippo
signaling via GPER in breast cancer. J Clin Invest. 125:2123–2135.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Zhao B, Ye X, Yu J, Li L, Li W, Li S, Yu
J, Lin JD, Wang CY, Chinnaiyan AM, et al: TEAD mediates
YAP-dependent gene induction and growth control. Genes Dev.
22:1962–1971. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Zanconato F, Forcato M, Battilana G,
Azzolin L, Quaranta E, Bodega B, Rosato A, Bicciato S, Cordenonsi M
and Piccolo S: Genome-wide association between YAP/TAZ/TEAD and
AP-1 at enhancers drives oncogenic growth. Nat Cell Biol.
17:1218–1227. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Escoll M, Gargini R, Cuadrado A, Anton IM
and Wandosell F: Mutant p53 oncogenic functions in cancer stem
cells are regulated by WIP through YAP/TAZ. Oncogene. 36:3515–3527.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Cordenonsi M, Zanconato F, Azzolin L,
Forcato M, Rosato A, Frasson C, Inui M, Montagner M, Parenti AR,
Poletti A, et al: The Hippo transducer TAZ confers cancer stem
cell-related traits on breast cancer cells. Cell. 147:759–772.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Hiemer SE, Szymaniak AD and Varelas X: The
transcriptional regulators TAZ and YAP direct transforming growth
factor β-induced tumorigenic phenotypes in breast cancer cells. J
Biol Chem. 289:13461–13474. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Bhat KP, Salazar KL, Balasubramaniyan V,
Wani K, Heathcock L, Hollingsworth F, James JD, Gumin J, Diefes KL,
Kim SH, et al: The transcriptional coactivator TAZ regulates
mesenchymal differentiation in malignant glioma. Genes Dev.
25:2594–2609. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Lau AN, Curtis SJ, Fillmore CM, Rowbotham
SP, Mohseni M, Wagner DE, Beede AM, Montoro DT, Sinkevicius KW,
Walton ZE, et al: Tumor-propagating cells and Yap/Taz activity
contribute to lung tumor progression and metastasis. EMBO J.
33:468–481. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Tsutsumi R, Masoudi M, Takahashi A, Fujii
Y, Hayashi T, Kikuchi I, Satou Y, Taira M and Hatakeyama M: YAP and
TAZ, Hippo signaling targets, act as a rheostat for nuclear SHP2
function. Dev Cell. 26:658–665. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Bae JS, Kim SM and Lee H: The Hippo
signaling pathway provides novel anti-cancer drug targets.
Oncotarget. 8:16084–16098. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Tao Y, Cai F, Shan L, Jiang H, Ma L and Yu
Y: The Hippo signaling pathway: An emerging anti-cancer drug
target. Discov Med. 24:7–18. 2017.PubMed/NCBI
|
|
93
|
Zanconato F, Battilana G, Cordenonsi M and
Piccolo S: YAP/TAZ as therapeutic targets in cancer. Curr Opin
Pharmacol. 29:26–33. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Enzo E, Santinon G, Pocaterra A, Aragona
M, Bresolin S, Forcato M, Grifoni D, Pession A, Zanconato F, Guzzo
G, et al: Aerobic glycolysis tunes YAP/TAZ transcriptional
activity. EMBO J. 34:1349–1370. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Wong W: Keeping cells from getting
Hippo-sized under energy stress. Sci Signal. 8:ec1082015.
View Article : Google Scholar
|
|
96
|
Mo JS, Meng Z, Kim YC, Park HW, Hansen CG,
Kim S, Lim DS and Guan KL: Cellular energy stress induces
AMPK-mediated regulation of YAP and the Hippo pathway. Nat Cell
Biol. 17:500–510. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
DeRan M, Yang J, Shen CH, Peters EC,
Fitamant J, Chan P, Hsieh M, Zhu S, Asara JM, Zheng B, et al:
Energy stress regulates hippo-YAP signaling involving AMPK-mediated
regulation of angiomotin-like 1 protein. Cell Reports. 9:495–503.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Santinon G, Pocaterra A and Dupont S:
Control of YAP/TAZ activity by metabolic and nutrient-sensing
pathways. Trends Cell Biol. 26:289–299. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Sorrentino G, Ruggeri N, Specchia V,
Cordenonsi M, Mano M, Dupont S, Manfrin A, Ingallina E, Sommaggio
R, Piazza S, et al: Metabolic control of YAP and TAZ by the
mevalonate pathway. Nat Cell Biol. 16:357–366. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Nallet-Staub F, Marsaud V, Li L, Gilbert
C, Dodier S, Bataille V, Sudol M, Herlyn M and Mauviel A:
Pro-invasive activity of the Hippo pathway effectors YAP and TAZ in
cutaneous melanoma. J Invest Dermatol. 134:123–132. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Zhao B, Li L, Lu Q, Wang LH, Liu CY, Lei Q
and Guan KL: Angiomotin is a novel Hippo pathway component that
inhibits YAP oncoprotein. Genes Dev. 25:51–63. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Hsu YL, Hung JY, Chou SH, Huang MS, Tsai
MJ, Lin YS, Chiang SY, Ho YW, Wu CY and Kuo PL: Angiomotin
decreases lung cancer progression by sequestering oncogenic YAP/TAZ
and decreasing Cyr61 expression. Oncogene. 34:4056–4068. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Pegoraro S, Ros G, Ciani Y, Sgarra R,
Piazza S and Manfioletti G: A novel HMGA1-CCNE2-YAP axis regulates
breast cancer aggressiveness. Oncotarget. 6:19087–19101. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Wilson KE, Li YW, Yang N, Shen H, Orillion
AR and Zhang J: PTPN14 forms a complex with Kibra and LATS1
proteins and negatively regulates the YAP oncogenic function. J
Biol Chem. 289:23693–23700. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Huang JM, Nagatomo I, Suzuki E, Mizuno T,
Kumagai T, Berezov A, Zhang H, Karlan B, Greene MI and Wang Q: YAP
modifies cancer cell sensitivity to EGFR and survivin inhibitors
and is negatively regulated by the non-receptor type protein
tyrosine phosphatase 14. Oncogene. 32:2220–2229. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Gao Y, Shi Q, Xu S, Du C, Liang L, Wu K,
Wang K, Wang X, Chang LS, He D, et al: Curcumin promotes KLF5
proteasome degradation through downregulating YAP/TAZ in bladder
cancer cells. Int J Mol Sci. 15:15173–15187. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Oku Y, Nishiya N, Shito T, Yamamoto R,
Yamamoto Y, Oyama C and Uehara Y: Small molecules inhibiting the
nuclear localization of YAP/TAZ for chemotherapeutics and
chemosensitizers against breast cancers. FEBS Open Bio. 5:542–549.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Rosenbluh J, Nijhawan D, Cox AG, Li X,
Neal JT, Schafer EJ, Zack TI, Wang X, Tsherniak A, Schinzel AC, et
al: β-Catenin-driven cancers require a YAP1 transcriptional complex
for survival and tumorigenesis. Cell. 151:1457–1473. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Rao J and Li N: Microfilament actin
remodeling as a potential target for cancer drug development. Curr
Cancer Drug Targets. 4:345–354. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Morikawa Y, Zhang M, Heallen T, Leach J,
Tao G, Xiao Y, Bai Y, Li W, Willerson JT and Martin JF: Actin
cytoskeletal remodeling with protrusion formation is essential for
heart regeneration in Hippo-deficient mice. Sci Signal. 8:ra412015.
View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Kim MH and Kim J, Hong H, Lee SH, Lee JK,
Jung E and Kim J: Actin remodeling confers BRAF inhibitor
resistance to melanoma cells through YAP/TAZ activation. EMBO J.
35:462–478. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Ferrarelli LK: Actin against BRAF
inhibitors. Sci Signal. 9:ec512016. View Article : Google Scholar
|
|
113
|
Wang P, Bai Y, Song B, Wang Y, Liu D, Lai
Y, Bi X and Yuan Z: PP1A-mediated dephosphorylation positively
regulates YAP2 activity. PLoS One. 6:e242882011. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Mao B, Hu F, Cheng J, Wang P, Xu M, Yuan
F, Meng S, Wang Y, Yuan Z and Bi W: SIRT1 regulates YAP2-mediated
cell proliferation and chemoresistance in hepatocellular carcinoma.
Oncogene. 33:1468–1474. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Imanaka Y, Tsuchiya S, Sato F, Shimada Y,
Shimizu K and Tsujimoto G: MicroRNA-141 confers resistance to
cisplatin-induced apoptosis by targeting YAP1 in human esophageal
squamous cell carcinoma. J Hum Genet. 56:270–276. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Zhou Z, Hao Y, Liu N, Raptis L, Tsao MS
and Yang X: TAZ is a novel oncogene in non-small cell lung cancer.
Oncogene. 30:2181–2186. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Anastasiadou E, Jacob LS and Slack FJ:
Non-coding RNA networks in cancer. Nat Rev Cancer. 18:5–18. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Esteller M: Non-coding RNAs in human
disease. Nat Rev Genet. 12:861–874. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
He L and Hannon GJ: MicroRNAs: Small RNAs
with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Stefani G and Slack FJ: Small non-coding
RNAs in animal development. Nat Rev Mol Cell Biol. 9:219–230. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Sassen S, Miska EA and Caldas C: MicroRNA:
Implications for cancer. Virchows Arch. 452:1–10. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Kim HS, Lee KS, Bae HJ, Eun JW, Shen Q,
Park SJ, Shin WC, Yang HD, Park M, Park WS, et al: MicroRNA-31
functions as a tumor suppressor by regulating cell cycle and
epithelial-mesenchymal transition regulatory proteins in liver
cancer. Oncotarget. 6:8089–8102. 2015.PubMed/NCBI
|
|
124
|
Lin S and Gregory RI: MicroRNA biogenesis
pathways in cancer. Nat Rev Cancer. 15:321–333. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Nishikawa R, Goto Y, Kojima S, Enokida H,
Chiyomaru T, Kinoshita T, Sakamoto S, Fuse M, Nakagawa M, Naya Y,
et al: Tumor-suppressive microRNA-29s inhibit cancer cell migration
and invasion via targeting LAMC1 in prostate cancer. Int J Oncol.
45:401–410. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Nishikawa R, Goto Y, Sakamoto S, Chiyomaru
T, Enokida H, Kojima S, Kinoshita T, Yamamoto N, Nakagawa M, Naya
Y, et al: Tumor-suppressive microRNA-218 inhibits cancer cell
migration and invasion via targeting of LASP1 in prostate cancer.
Cancer Sci. 105:802–811. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Ouyang H, Gore J, Deitz S and Korc M:
microRNA-10b enhances pancreatic cancer cell invasion by
suppressing TIP30 expression and promoting EGF and TGF-β actions.
Oncogene. 33:4664–4674. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Cirilo PDR, de Sousa Andrade LN, Corrêa
BRS, Qiao M, Furuya TK, Chammas R and Penalva LOF: MicroRNA-195
acts as an anti-proliferative miRNA in human melanoma cells by
targeting Prohibitin 1. BMC Cancer. 17:7502017. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Halytskiy V: Shifts in miRNA expression
pattern can lead to the loss of contact inhibition in breast cancer
cells. Eur J Cancer. 57 Suppl 2:S1162016.
|
|
130
|
Liu P, Zhang H, Liang X, Ma H, Luan F,
Wang B, Bai F, Gao L and Ma C: HBV preS2 promotes the expression of
TAZ via miRNA-338-3p to enhance the tumorigenesis of hepatocellular
carcinoma. Oncotarget. 6:29048–29059. 2015.PubMed/NCBI
|
|
131
|
Higashi T, Hayashi H, Ishimoto T, Takeyama
H, Kaida T, Arima K, Taki K, Sakamoto K, Kuroki H, Okabe H, et al:
miR-9-3p plays a tumour-suppressor role by targeting TAZ (WWTR1) in
hepatocellular carcinoma cells. Br J Cancer. 113:252–258. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Liu AM, Poon RT and Luk JM: MicroRNA-375
targets Hippo-signaling effector YAP in liver cancer and inhibits
tumor properties. Biochem Biophys Res Commun. 394:623–627. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Tan G, Cao X, Dai Q, Zhang B, Huang J,
Xiong S, Zhang Y, Chen W, Yang J and Li H: A novel role for
microRNA-129-5p in inhibiting ovarian cancer cell proliferation and
survival via direct suppression of transcriptional co-activators
YAP and TAZ. Oncotarget. 6:8676–8686. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Hua K, Yang W, Song H, Song J, Wei C, Li D
and Fang L: Up-regulation of miR-506 inhibits cell growth and
disrupt the cell cycle by targeting YAP in breast cancer cells. Int
J Clin Exp Med. 8:12018–12027. 2015.PubMed/NCBI
|
|
135
|
Zhang S, Liu Z, Wu L and Wang Y: MiR-361
targets Yes-associated protein (YAP) mRNA to suppress cell
proliferation in lung cancer. Biochem Biophys Res Commun.
492:468–473. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Lo Sardo F, Forcato M, Sacconi A, Capaci
V, Zanconato F, Di Agostino S, Del Sal G, Pandolfi PP, Strano S,
Bicciato S, et al: MCM7 and its hosted miR-25, 93 and 106b cluster
elicit YAP/TAZ oncogenic activity in lung cancer. Carcinogenesis.
38:64–75. 2017. View Article : Google Scholar : PubMed/NCBI
|
